Close X

Attorney Spotlight

How does Eli Richardson's past work with the federal government inform his client interactions? Find out more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

In June 2016, AmSurg Corp. and Envision Healthcare Holdings, Inc. (Envision) announced they have signed a definitive merger agreement pursuant to which the companies will combine in an all-stock transaction. Upon completion of the merger, which is expected to be tax-free to the shareholders of both organizations, the combined company will be named Envision Healthcare Corporation and co-headquartered in Nashville, Tennessee and Greenwood Village, Colorado. The company's common stock is expected to trade on the New York Stock Exchange under the ticker symbol: EVHC. Bass, Berry & Sims served as lead counsel on the transaction, led by Jim Jenkins. Read more.

AmSurg logo


Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Inside the FCA blogInside the FCA blog features ongoing updates related to the False Claims Act (FCA), including insight on the latest legal decisions, regulatory developments and FCA settlements. The blog provides timely updates for corporate boards, directors, compliance managers, general counsel and other parties interested in the organizational impact and legal developments stemming from issues potentially giving rise to FCA liability.

Read More >

District Court Issues Opinion on Supreme Court Holding in Halliburton

Publications

August 28, 2015

On July 27, 2015, the U.S. District Court for the Northern District of Texas issued its opinion on remand of Halliburton, Co. v. Erica P. John Fund, Inc., 134 S. Ct. 2398 (2014) (Halliburton II), providing a glimpse into how the U.S. Supreme Court's holding in this case will be applied by district courts going forward. Erica P. John Fund, Inc. v. Halliburton Co., No. 3:02-CV-1152-M, slip op. at 1 (N.D. Tex. July 25, 2015). As discussed in our June 2014 alert, in Halliburton II the Supreme Court held that a defendant in a securities fraud class action can introduce evidence of a lack of price impact at the class certification stage to rebut the "fraud on the market" presumption of reliance.

The opinion by U.S. District Judge Barbara Lynn showed that the Supreme Court's holding in Halliburton II may have teeth going forward. Judge Lynn thoroughly applied the Supreme Court's holding in Halliburton II, carefully analyzing the economic arguments proposed by the defendants in her 53-page opinion. Judge Lynn spent the majority of her opinion comparing the methodologies and findings of the economists hired by Halliburton and the Erica P. John Fund, suggesting that the class certification stage of proceedings may become a "battle of the experts" going forward. While Judge Lynn was convinced by Halliburton's experts that five of the purported corrective disclosures at issue did not have a statistically significant impact on Halliburton's share price, she found that Defendants had not met their burden of showing that disclosure of a $30 million jury verdict against a subsidiary did not impact Halliburton's share price (which had plunged 40 percent), justifying certification with regard to that single disclosure. The opinion is significant because it demonstrates that, depending on the right set of underlying facts, Halliburton II can be used by securities class action defendants to ward off, or at least narrow, class certification, provided they are willing to spend the time and money to hire economics experts and conduct price impact studies.

Judge Lynn also dedicated a substantial portion of her opinion to the issue of burden-shifting. Judge Lynn joined other district court judges in holding that defendants bear the burden of proving that alleged corrective disclosures did not affect the company's share price. Judge Lynn also rejected Halliburton's argument that investors must prove at the class certification that supposed corrective disclosures were, in fact, corrective of alleged misrepresentations, referring to this argument as "a veiled attempt to assert the 'truth on the market' defense," which the Court found was not properly an issue at this stage of the litigation.


Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.